Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Lin KK, Harrell MI, Oza AM, Oaknin A, Ray-Coquard I, Tinker AV, Helman E, Radke MR, Say C, Vo LT, Mann E, Isaacson JD, Maloney L, O'Malley DM, Chambers SK, Kaufmann SH, Scott CL, Konecny GE, Coleman RL, Sun JX, Giordano H, Brenton JD, Harding TC, McNeish IA, Swisher EM.

Cancer Discov. 2019 Feb;9(2):210-219. doi: 10.1158/2159-8290.CD-18-0715. Epub 2018 Nov 13.

2.

Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.

Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.

3.

Pharmacokinetic Study of Rucaparib in Patients With Advanced Solid Tumors.

Shapiro GI, Kristeleit RS, Burris HA, LoRusso P, Patel MR, Drew Y, Giordano H, Maloney L, Watkins S, Goble S, Jaw-Tsai S, Xiao JJ.

Clin Pharmacol Drug Dev. 2019 Jan;8(1):107-118. doi: 10.1002/cpdd.575. Epub 2018 May 25.

4.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Coleman RL, Oza AM, Lorusso D, Aghajanian C, Oaknin A, Dean A, Colombo N, Weberpals JI, Clamp A, Scambia G, Leary A, Holloway RW, Gancedo MA, Fong PC, Goh JC, O'Malley DM, Armstrong DK, Garcia-Donas J, Swisher EM, Floquet A, Konecny GE, McNeish IA, Scott CL, Cameron T, Maloney L, Isaacson J, Goble S, Grace C, Harding TC, Raponi M, Sun J, Lin KK, Giordano H, Ledermann JA; ARIEL3 investigators.

Lancet. 2017 Oct 28;390(10106):1949-1961. doi: 10.1016/S0140-6736(17)32440-6. Epub 2017 Sep 12. Erratum in: Lancet. 2017 Oct 28;390(10106):1948.

5.

Antitumor activity and safety of the PARP inhibitor rucaparib in patients with high-grade ovarian carcinoma and a germline or somatic BRCA1 or BRCA2 mutation: Integrated analysis of data from Study 10 and ARIEL2.

Oza AM, Tinker AV, Oaknin A, Shapira-Frommer R, McNeish IA, Swisher EM, Ray-Coquard I, Bell-McGuinn K, Coleman RL, O'Malley DM, Leary A, Chen LM, Provencher D, Ma L, Brenton JD, Konecny GE, Castro CM, Giordano H, Maloney L, Goble S, Lin KK, Sun J, Raponi M, Rolfe L, Kristeleit RS.

Gynecol Oncol. 2017 Nov;147(2):267-275. doi: 10.1016/j.ygyno.2017.08.022. Epub 2017 Sep 4.

6.

Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma.

Kondrashova O, Nguyen M, Shield-Artin K, Tinker AV, Teng NNH, Harrell MI, Kuiper MJ, Ho GY, Barker H, Jasin M, Prakash R, Kass EM, Sullivan MR, Brunette GJ, Bernstein KA, Coleman RL, Floquet A, Friedlander M, Kichenadasse G, O'Malley DM, Oza A, Sun J, Robillard L, Maloney L, Bowtell D, Giordano H, Wakefield MJ, Kaufmann SH, Simmons AD, Harding TC, Raponi M, McNeish IA, Swisher EM, Lin KK, Scott CL; AOCS Study Group.

Cancer Discov. 2017 Sep;7(9):984-998. doi: 10.1158/2159-8290.CD-17-0419. Epub 2017 Jun 6.

7.

A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors.

Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmaña J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R.

Clin Cancer Res. 2017 Aug 1;23(15):4095-4106. doi: 10.1158/1078-0432.CCR-16-2796. Epub 2017 Mar 6.

8.

A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours.

Wilson RH, Evans TJ, Middleton MR, Molife LR, Spicer J, Dieras V, Roxburgh P, Giordano H, Jaw-Tsai S, Goble S, Plummer R.

Br J Cancer. 2017 Mar 28;116(7):884-892. doi: 10.1038/bjc.2017.36. Epub 2017 Feb 21.

9.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Swisher EM, Lin KK, Oza AM, Scott CL, Giordano H, Sun J, Konecny GE, Coleman RL, Tinker AV, O'Malley DM, Kristeleit RS, Ma L, Bell-McGuinn KM, Brenton JD, Cragun JM, Oaknin A, Ray-Coquard I, Harrell MI, Mann E, Kaufmann SH, Floquet A, Leary A, Harding TC, Goble S, Maloney L, Isaacson J, Allen AR, Rolfe L, Yelensky R, Raponi M, McNeish IA.

Lancet Oncol. 2017 Jan;18(1):75-87. doi: 10.1016/S1470-2045(16)30559-9. Epub 2016 Nov 29.

10.

Coherence of brain electrical activity: a quality of life indicator in Alzheimer's disease?

Fonseca LC, Tedrus GM, Rezende AL, Giordano HF.

Arq Neuropsiquiatr. 2015 May;73(5):396-401. doi: 10.1590/0004-282X20150035.

11.

Feasibility and outcome of haploidentical SCT in pediatric high-risk hematologic malignancies and Fanconi anemia in Uruguay.

Dufort G, Pisano S, Incoronato A, Castiglioni M, Carracedo M, Pagés C, Simon E, Zuccolo S, Barcelona R, Mezzano R, Tiscornia A, Lemos F, Morosini F, Schelotto M, Giordano H, Carreto E, Bengoechea M, Boggia B, Rodriguez I, Guerrero L, Dabezies A, Castillo L.

Bone Marrow Transplant. 2012 May;47(5):663-8. doi: 10.1038/bmt.2011.148. Epub 2011 Jul 18.

PMID:
21765479
12.

Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.

Garcia-Manero G, Gore SD, Cogle C, Ward R, Shi T, Macbeth KJ, Laille E, Giordano H, Sakoian S, Jabbour E, Kantarjian H, Skikne B.

J Clin Oncol. 2011 Jun 20;29(18):2521-7. doi: 10.1200/JCO.2010.34.4226. Epub 2011 May 16.

13.

[Massive and fulminant pulmonary embolism after central catheter removal].

Alcaide Matas F, Del Barrio Molina MM, Campano Cruz I, Giordano H, García Olives F.

Cir Esp. 2010 Feb;87(2):125-6. doi: 10.1016/j.ciresp.2008.09.016. Epub 2009 Nov 25. Spanish. No abstract available.

PMID:
19939353
14.

Vitamin K supplementation does not significantly impact bone mineral density and biochemical markers of bone in pre- and perimenopausal women.

Volpe SL, Leung MM, Giordano H.

Nutr Res. 2008 Sep;28(9):577-82. doi: 10.1016/j.nutres.2008.06.006.

PMID:
19083462
15.

Chronic liver disease in kidney recipients with hepatitis C virus infection.

Giordano HM, França AV, Meirelles L, Escanhoela CA, Nishimura NF, Santos RL, Quadros KR, Mazzali M, Alves-Filho G, Soares EC.

Clin Transplant. 2003 Jun;17(3):195-9.

PMID:
12780667
16.

Five days of ceftriaxone to treat spontaneous bacterial peritonitis in cirrhotic patients.

França A, Giordano HM, Sevá-Pereira T, Soares EC.

J Gastroenterol. 2002;37(2):119-22.

PMID:
11871762
17.
18.
19.

Simultaneous PML/RARalpha and AML1/ETO expression with t(15;17) at onset and relapse with only t(8;21) in an acute promyelocytic leukemia patient.

Bonomi R, Giordano H, del Pilar Moreno M, Bodega E, Landoni AI, Gallagher R, del Rosario Uriarte M.

Cancer Genet Cytogenet. 2000 Nov;123(1):41-3.

PMID:
11120332
20.

Evaluation of hematopoietic progenitors in hematopoietic progenitor cell transplants. CD34+ dose effect in marrow recovery. Retrospective analysis in 38 patients.

Gabús R, Magariños A, Zamora M, De Lisa E, Landoni AI, Martínez G, Canessa C, Giordano H, Bodega E.

Hematol Cell Ther. 1999 Aug;41(4):171-7.

PMID:
10543373
21.

High-throughput screening assay for helicase enzymes.

Sivaraja M, Giordano H, Peterson MG.

Anal Biochem. 1998 Dec 1;265(1):22-7.

PMID:
9866703
22.
23.

Evidence for a strain-stabilized bct phase of cobalt deposited on Pd{100}: An x-ray photoelectron diffraction study.

Giordano H, Atrei A, Torrini M, Bardi U, Gleeson M, Barnes C.

Phys Rev B Condens Matter. 1996 Oct 15;54(16):11762-11768. No abstract available.

PMID:
9984967
24.

Spatial regulation of Drosophila snake protease activity in the generation of dorsal-ventral polarity.

Smith CL, Giordano H, Schwartz M, DeLotto R.

Development. 1995 Dec;121(12):4127-35.

26.

Radionuclide evaluation of left-ventricular function in chronic Chagas' cardiomyopathy.

Arreaza N, Puigbó JJ, Acquatella H, Casal H, Giordano H, Valecillos R, Mendoza I, Pérez JF, Hirschhaut E, Combellas I.

J Nucl Med. 1983 Jul;24(7):563-7.

27.

M-mode and two-dimensional echocardiography in chronic Chages' heart disease. A clinical and pathologic study.

Acquatella H, Schiller NB, Puigbó JJ, Giordano H, Suárez JA, Casal H, Arreaza N, Valecillos R, Hirschhaut E.

Circulation. 1980 Oct;62(4):787-99. No abstract available.

PMID:
7408151
28.

Diagnosis of Chagas' cardiomyopathy. Non-invasive techniques.

Puigbó JJ, Valecillos R, Hirschhaut E, Giordano H, Boccalandro I, Suárez C, Aparicio JM.

Postgrad Med J. 1977 Sep;53(623):527-32. Review.

29.

[Pharyngeal hemorrhages due to nasotracheal intubation for adenotonsillectomy].

Menezes RA, Spiegel P, da Silva JS, Giordano H.

Rev Bras Anestesiol. 1968 Jul-Sep;18(3):318-22. Portuguese. No abstract available.

PMID:
5721173
30.

[Intramuscular use of 10 percent sodium thiopental].

Fortes JD, Giordano HP, Varejão N.

Rev Bras Anestesiol. 1966 Oct-Dec;16(4):444-6. Portuguese. No abstract available.

PMID:
6011880
31.

THE BUREAU OF NARCOTICS AND AMERICAN PHARMACY.

GIORDANO HL.

Mil Med. 1965 Aug;130:763-7. No abstract available.

PMID:
14320575

Supplemental Content

Loading ...
Support Center